
Reinstate Aetna at Buy following Coventry acquisition via Goldman Sachs We have removed the NR designation from Aetna Inc. (NYSE:AET) shares. Aetna is now added to the Buy List with a 12-month price target of $68. Following acquisition of Coventry Health Care, Aetna has greater regional commercial market breadth/strength and is now much better positioned to leverage Medicaid and dual eligible growth opportunities. We also see further upside from Coventry Health Care, Inc. (NYSE:CVH) merger synergies in 2013-2016....
Read More »










